A new licensing push highlighted Lilly’s continued expansion in GLP biology with a $75 million upfront deal for Hanmi’s long-acting GLP-2 analog sonefpeglutide. Lilly secured exclusive worldwide development, manufacturing, and commercialization rights for all territories except Korea, where Hanmi retains rights. The deal is tied to additional development and milestone payments that could total $1.185 billion, with royalties available on commercialization. Hanmi’s global Phase 2 trial in short bowel syndrome (SBS) is expected to be completed as Lilly plans new studies based on existing nonclinical and clinical data. Sonefpeglutide leverages Hanmi’s long-acting protein/peptide discovery platform (LAPSCOVERY), supporting Lilly’s broader portfolio strategy as obesity drugs expand into gastrointestinal and other metabolic indications.